$country= Comparative statistics by cancer registry - SurvCan

Comparative statistics by cancer registry

Registry: Comparative statistics by cancer site

Table3: Comparison of 1-, 3- and 5-year absolute and relative survival and 5-year age-standardized relative survival (ASRS) by site

(Tianjin, China, 1991-1999 cases followed-up until 2000)

Click on cancer site (ICD-10 code) for comparison
SiteICD-10TotalAbsolute survival %Relative survival %ASRS% at 5-years
1-year3-year5-year1-year3-year5-yearall ages0-74 years
C00Lip5392.586.480.396.097.297.699.399.3
C01-02Tongue18771.159.259.272.963.967.868.368.2
C03-06Oral cavity25371.559.855.673.765.464.668.469.2
C07-08Salivary gland14188.779.778.790.785.488.987.288.3
C09Tonsil2588.079.072.790.487.187.275.668.3
C11Nasopharynx42175.360.950.576.764.355.354.157.6
C12-13Hypopharynx4774.565.465.477.272.978.680.982.3
C15Oesophagus320846.228.726.948.332.633.436.740.3
C16Stomach751652.336.834.454.340.941.341.144.2
C17Small intestine18171.355.750.472.959.757.453.957.8
C18Colon265569.555.652.571.660.961.461.361.9
C19-20Rectum250173.255.448.175.460.556.053.058.1
C21Anus4680.466.266.284.075.181.981.077.8
C22Liver652532.522.621.333.524.825.125.425.8
C23-24Gall bladder104249.940.339.151.845.047.347.550.3
C25Pancreas199036.426.025.237.628.629.830.331.0
C30-31Nose/Sinuses16777.262.958.578.967.466.672.661.6
C32Larynx103976.158.554.078.864.964.665.169.7
C33-34Lung2140343.627.625.745.130.730.931.332.3
C37-38Other thoracic organs24459.448.546.260.951.951.850.552.1
C40-41Bone68645.327.625.046.529.527.825.729.8
C43Melanoma skin11977.359.856.079.665.063.957.962.8
C44Other skin35082.676.372.885.785.589.089.786.7
C45Mesothelioma8458.349.849.860.154.458.560.658.1
C47+C49Connective tissue42583.373.371.985.077.979.881.078.7
C50Breast586391.884.379.892.987.284.882.385.6
C51Vulva5784.266.761.286.572.671.371.674.3
C53Cervix56771.858.553.873.863.762.468.570.5
C54Corpus uteri72292.287.385.593.390.691.391.091.3
C55Uterus unspecified28755.727.018.957.429.522.025.029.1
C56Ovary112477.262.759.778.265.163.662.164.4
C57Other female genital5280.866.160.981.968.664.349.967.5
C58Placenta6296.893.393.397.093.894.160.160.0
C60Penis6581.575.175.185.787.196.689.679.0
C61Prostate42374.559.252.579.171.272.071.468.4
C62Testis7378.168.866.878.870.068.674.976.4
C64Kidney109469.657.852.671.762.960.659.065.7
C65Renal pelvis14689.781.078.892.790.495.7101.293.9
C66Ureter6382.572.063.184.878.474.465.377.9
C67Urinary bladder202076.663.959.680.273.074.673.481.1
C69Eye3588.679.179.190.583.887.484.5100.3
C70-72Brain & nervous system194454.842.539.955.844.643.348.149.5
C73Thyroid61885.380.879.486.784.385.488.689.1
C74Adrenal gland5377.469.769.778.271.873.569.269.2
C75Other endocrine12196.796.796.797.498.9100.876.4105.2
C81Hodgkin lymphoma12391.183.777.892.086.081.181.081.9
C82-85+C96Non-Hodgkin lymphoma148160.146.542.861.649.848.051.153.2
C90Multiple myeloma21760.444.640.661.847.845.746.246.1
C91Lymphoid leukaemia30976.764.261.677.766.766.068.864.9
C92-94Myeloid leukaemia56775.566.563.176.569.267.668.268.0
C95Leukaemia unspecified61142.222.719.443.224.321.821.922.0


Graphs:


Other tables available for this registry:
- Table1: Data quality indices - Proportion (%) of histologically verified and death certificate only cases, number and proportion of included and excluded cases by site (Tianjin, China, 1991-1999 cases followed-up until 2000)
- Table2b: Number and proportion of cases by vital status and median follow-up (in months) by site (Tianjin, China, 1991-1999 cases followed-up until 2000)
- Table3: Comparison of 1-, 3- and 5-year absolute and relative survival and 5-year age-standardized relative survival (ASRS) by site (Tianjin, China, 1991-1999 cases followed-up until 2000)
- Table4: Site-wise number of cases, 5-year absolute and relative survival by sex and relative survival by age group (Tianjin, China, 1991-1999 cases followed-up until 2000)
- Table5: Comparison of 5-year absolute and relative survival of cases diagnosed between 1981-1990 and 1991-1999 (Tianjin, China)
- Table6: Up-to-date 5-year relative survival estimates using cohort and period approaches by site and calendar period (Tianjin, China, 1991-1999 cases followed-up until 2000)




Registry chapter:


Consult the chapter in Cancer survival in developping countries (Volume II)